stated Harvey J.

ARIAD Pharmaceuticals’ Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment ARIAD Pharmaceuticals, Inc. ‘We are delighted by the rapid acceptance of Iclusig in Europe and will now work closely with the national wellness authorities to make Iclusig open to Philadelphia-positive leukaemia sufferers as fast as possible,’ stated Harvey J . Berger, M.D., chairman and ceo of ARIAD. ‘The scientific development of Iclusig involved many leukaemia experts throughout Europe, and you want to identify their critical roles in getting Iclusig to patients with resistant or intolerant CML and Ph+ ALL in the EU.’ The most typical serious effects for Iclusig had been pancreatitis, abdominal pain, pyrexia, anaemia, febrile neutropenia, decrease in platelet count and neutrophil count, pancytopenia, myocardial infarction, diarrhea, and elevated lipase.

To stimulate an international discussion on this subject, the APS Clinical Study Task Force is usually hosting a summit titled, Breaking From the Container, in Miami from Nov. 2-4, 2010. The duty force, co-chaired by Medical center for Special Medical procedures physician-scientists Doruk Erkan, M.D., and Michael D. Lockshin, M.D., was created due to the 13th International Congress on Antiphospholipid Antibodies in April 2010. The two dozen summit attendees shall include experts in the field of APS research from around the world, including Australia, Brazil, Italy, the Netherlands, the United Kingdom and america.